全文获取类型
收费全文 | 1308篇 |
免费 | 103篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 8篇 |
妇产科学 | 19篇 |
基础医学 | 173篇 |
口腔科学 | 12篇 |
临床医学 | 125篇 |
内科学 | 476篇 |
皮肤病学 | 6篇 |
神经病学 | 92篇 |
特种医学 | 119篇 |
外科学 | 81篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 49篇 |
眼科学 | 4篇 |
药学 | 142篇 |
中国医学 | 1篇 |
肿瘤学 | 96篇 |
出版年
2024年 | 5篇 |
2023年 | 25篇 |
2022年 | 13篇 |
2021年 | 27篇 |
2020年 | 32篇 |
2019年 | 40篇 |
2018年 | 41篇 |
2017年 | 32篇 |
2016年 | 44篇 |
2015年 | 44篇 |
2014年 | 60篇 |
2013年 | 62篇 |
2012年 | 100篇 |
2011年 | 97篇 |
2010年 | 67篇 |
2009年 | 44篇 |
2008年 | 83篇 |
2007年 | 89篇 |
2006年 | 82篇 |
2005年 | 77篇 |
2004年 | 79篇 |
2003年 | 67篇 |
2002年 | 68篇 |
2001年 | 11篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 13篇 |
1997年 | 12篇 |
1996年 | 6篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1993年 | 7篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 4篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1970年 | 2篇 |
排序方式: 共有1417条查询结果,搜索用时 10 毫秒
61.
Tayeb Kakeshpour Belhu Metaferia Richard N. Zare Adriaan Bax 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(8)
Hydrogen peroxide (H2O2) plays a key role in environmental chemistry, biology, and medicine. H2O2 concentrations typically are 6 to 10 orders of magnitude lower than that of water, making its quantitative detection challenging. We demonstrate that optimized NMR spectroscopy allows direct, interference-free, quantitative measurements of H2O2 down to submicromolar levels in a wide range of fluids, ranging from exhaled breath and air condensate to rain, blood, urine, and saliva. NMR measurements confirm the previously reported spontaneous generation of H2O2 in microdroplets that form when condensing water vapor on a hydrophobic surface, which can interfere with atmospheric H2O2 measurements. Its antimicrobial activity and strong seasonal variation speculatively could be linked to the seasonality of respiratory viral diseases. 相似文献
62.
Effects of sildenafil on cardiac structure and function,cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension 下载免费PDF全文
63.
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study 下载免费PDF全文
John R. Teerlink Adriaan A. Voors Piotr Ponikowski Peter S. Pang Barry H. Greenberg Gerasimos Filippatos G. Michael Felker Beth A. Davison Gad Cotter Claudio Gimpelewicz Leandro Boer‐Martins Margaret Wernsing Tsushung A. Hua Thomas Severin Marco Metra 《European journal of heart failure》2017,19(6):800-809
Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX‐AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all‐cause and cardiovascular mortality by 37% through day 180. RELAX‐AHF‐2 ( ClinicalTrials.gov NCT01870778) is designed to confirm serelaxin's effect on these clinical outcomes. RELAX‐AHF‐2 is a multicentre, randomized, double‐blind, placebo‐controlled, event‐driven, phase 3 trial enrolling ~6800 patients hospitalized for AHF with dyspnoea, congestion on chest radiograph, increased natriuretic peptide levels, mild‐to‐moderate renal insufficiency, and systolic blood pressure ≥125 mmHg. Patients are randomized within 16 h of presentation to 48 h intravenous infusions of serelaxin (30 µg/kg/day) or placebo, both in addition to standard of care treatments. The primary objectives are to demonstrate that serelaxin is superior to placebo in reducing: (i) 180 day cardiovascular death, and (ii) occurrence of WHF through day 5. Key secondary endpoints include 180 day all‐cause mortality, composite of 180 day combined cardiovascular mortality or heart failure/renal failure rehospitalization, and in‐hospital length of stay during index AHF. The results from RELAX‐AHF‐2 will provide data on the potential beneficial effect of serelaxin on cardiovascular mortality and WHF in selected patients with AHF. 相似文献
64.
Satit Janwanishstaporn Siting Feng John Teerlink Marco Metra Gad Cotter Beth A. Davison G. Michael Felker Gerasimos Filippatos Peter Pang Piotr Ponikowski Thomas Severin Claudio Gimpelewicz Thomas Holbro Chien Wei Chen Iziah Sama Adriaan A. Voors Barry H. Greenberg 《European journal of heart failure》2020,22(4):726-738
65.
66.
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency 下载免费PDF全文
Stefan D. Anker Stefan Schroeder Dan Atar Jeroen J. Bax Claudio Ceconi Martin R. Cowie Adam Crisp Fabienne Dominjon Ian Ford Hossein‐Ardeschir Ghofrani Savion Gropper Gerhard Hindricks Mark A. Hlatky Richard Holcomb Narimon Honarpour J. Wouter Jukema Albert M. Kim Michael Kunz Martin Lefkowitz Chantal Le Floch Ulf Landmesser Theresa A. McDonagh John J. McMurray Bela Merkely Milton Packer Krishna Prasad James Revkin Giuseppe M.C. Rosano Ransi Somaratne Wendy Gattis Stough Adriaan A. Voors Frank Ruschitzka 《European journal of heart failure》2016,18(5):482-489
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research. 相似文献
67.
68.
69.
70.